Yongbin Chen

Yongbin Chen

Auto-generated profile, based on publicly available information

Yongbin Chen

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SJScott M. Johnson
Scott M. Johnson
HBHanmei Bao
Hanmei Bao
CMCailin E. McMahon
Cailin E. McMahon
YCYongbin Chen
Yongbin Chen
SBStephanie D. Burr
Stephanie D. Burr
JLJun Liu
Jun Liu
The I148M variant of PNPLA3 is closely associated with hepatic steatosis. Recent evidence indicates that the I148M mutant functions as an inhibitor of PNPLA2/ATGL-mediated lipolysis, leaving the role of wild-type PNPLA3 undefined. Despite showing a triglyceride hydrolase activity in vitro, PNPLA3 has yet to be established as a lipase in vivo. Here, we show that PNPLA3 preferentially hydrolyzes polyunsaturated triglycerides, mobilizing polyunsaturated fatty acids for phospholipid desaturation and enhancing hepatic secretion of triglyceride-rich lipoproteins. Under lipogenic conditions, mice with liver-specific knockout or acute knockdown of PNPLA3 exhibit aggravated liver steatosis and reduced plasma VLDL-triglyceride levels. Similarly, I148M-knockin mice show decreased hepatic triglyceride secretion during lipogenic stimulation. Our results highlight a specific context whereby the wild-type PNPLA3 facilitates the balance between hepatic triglyceride storage and secretion, and suggest the potential contribution of a loss-of-function by the I148M variant to the development of fatty liver disease in humans.

13 April 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
DPDavide Povero
Davide Povero
YCYongbin Chen
Yongbin Chen
SJScott M. Johnson
Scott M. Johnson
CMCailin E. McMahon
Cailin E. McMahon
MPMeixia Pan
Meixia Pan
JLJun Liu
Jun Liu

28 August 2022 in Cardiovascular Digital Health Journal
Verified
Journal Article
Open access
QDQiying Dai
Qiying Dai
ASAkil Adrian Sherif
Akil Adrian Sherif
CJChengyue Jin
Chengyue Jin
YCYongbin Chen
Yongbin Chen
PCPeng Cai
Peng Cai
PLPengyang Li
Pengyang Li
Sarcoidosis with cardiac involvement, although rare, has a worse prognosis than sarcoidosis involving other organ systems. We used a large dataset to train machine learning models to predict in-hospital mortality among sarcoidosis patients admitted with heart failure (HF). Utilizing the National Inpatient Sample, we identified 4659 patients hospitalized with a primary diagnosis of HF. In this cohort, we identified patients with a secondary diagnosis of sarcoidosis using International Statistical Classification of Disease, Tenth Revision (ICD-10) codes. Patients were separated into a training group and a testing group in a 7:3 ratio. Least absolute shrinkage and selection operator regression was used to select variables to prevent model overfitting or underfitting. For machine learning models, logistic regression, random forest, and XGBoosting were applied in the training group. Parameters in each of the models were tuned using the GridSearchCV function. After training, all models were further validated in the testing group. Models were then evaluated using the area under curve (AUC) score, sensitivity, and specificity. A total of 2.3% of sarcoidosis patients died in HF admission. Our machine learning model analysis found the RF model to have the highest AUC score and sensitivity. Feature analysis found that comorbid arrhythmias and fluid electrolyte disorders were the strongest factors in predicting in-hospital mortality. Machine learning methods can be useful in identifying predictors of in-hospital mortality in a given dataset.

8 January 2026 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
XZXiao Zhang
Xiao Zhang
SPSreejith S. Panicker
Sreejith S. Panicker
JBJordan M. Bollinger
Jordan M. Bollinger
AMAnurag Majumdar
Anurag Majumdar
RKRami Kheireddine
Rami Kheireddine
ESErica L. Scheller
Erica L. Scheller
Several adipose depots, including constitutive bone marrow adipose tissue, resist conventional lipolytic cues. However, under starvation, wasting or cachexia, the body eventually catabolizes stable adipocytes through unknown mechanisms. Here we developed a mouse model of brain-evoked depletion of all fat, including stable constitutive bone marrow adipose tissue, independent of food intake, to study this phenomenon. Genetic, surgical and chemical approaches demonstrated that catabolism of stable adipocytes required adipose triglyceride lipase-dependent lipolysis but was independent of local nerves, the sympathetic nervous system and catecholamines. Instead, concurrent hypoglycaemia and hypoinsulinaemia activated a potent catabolic state by suppressing lipid storage and increasing catecholamine-independent lipolysis via downregulation of cell-autonomous lipolytic inhibitors including G0s2. This was also sufficient to delipidate classical adipose depots and was recapitulated in tumour-associated cachexic mice. Overall, this defines unique adaptations of stable adipocytes to resist lipolysis in healthy states while isolating a potent catecholamine-independent neurosystemic pathway by which the body can rapidly catabolize all adipose tissues.

24 May 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
Nansu ZongNansu Zong
Nansu Zong
SCShaika Chowdhury
Shaika Chowdhury
SZShibo Zhou
Shibo Zhou
SRSivaraman Rajaganapathy
Sivaraman Rajaganapathy
YYYue Yu
Yue Yu
JCJames Cerhan
James Cerhan
The complexities inherent in EHR data create discrepancies between real-world evidence and RCTs, posing substantial challenges in determining whether a treatment is likely to have a beneficial impact compared to the standard of care in RCTs. The objective of this study is to enhance the prediction of efficacy direction for repurposed drugs tested in RCTs for heart failure (HF). To achieve this, we propose an efficacy direction prediction framework that integrates drug-target predictions with EHR-based Emulation Trials (ET) to derive surrogate endpoints for prediction using HF prognostic markers. Our validation of the proposed novel drug-target prediction model against the BETA benchmark demonstrates superior performance, surpassing existing baseline algorithms. Furthermore, an evaluation of our framework in identifying 17 repurposed drugs—derived from 266 phase 3 HF RCTs—using data from 59,000 patients at the Mayo Clinic highlights its remarkable predictive accuracy.

3 September 2023
Verified
Conference Paper
Open access
SCShaika Chowdhury
Shaika Chowdhury
YCYongbin Chen
Yongbin Chen
XMXiao Ma
Xiao Ma
QDQiying Dai
Qiying Dai
YYYue Yu
Yue Yu
Nansu ZongNansu Zong
Nansu Zong
Arterial hypertension is a major risk factor for heart failure and antihypertensives such as angiotensin converting enzyme (ACE) inhibitors and β-blockers are considered as its first-line treatment. Drug response prediction models designed to determine the most effective antihypertensive drug for a patient are hindered by the interpatient response variability. Although typically pharmacogenetic data have been used to investigate the association of genetic variants with the antihypertensive response, genomewide association studies are currently expensive and the translation of genotype guided antihypertensive therapy to clinical practice is challenging. With the generation of electronic health records (EHR) data summarized over the patient’s disease prognosis and interventions, it is still an underused resource for antihypertensive effectiveness studies in heart failure management. In this study, we first use the clinical events in the EHR related to the patient’s hard clinical endpoints and biomarkers associated with the heart failure condition to design selection strategies that determine the antihypertensive effectiveness, then develop annotated corpora using the strategies and eventually evaluate supervised deep learning classifiers on the annotated data. We annotated the EHR sequences of approximately 9500 patients with binary labels corresponding to the drug effectiveness across two different antihypertensive classes and our trained classifier was able to obtain the best F1 performance of 0.97.